Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 52 full-time employees. The firm is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer`s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. The company has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Website: vtvtherapeutics.com



Growth: Good revenue growth rate 100.0%, there is acceleration compared to average historical growth rates 12.5%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -266.7%. On average the margin is decreasing steadily. Gross margin is low, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 204.9% higher than minimum and 77.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -9.6x by EV / Sales multiple

Key Financials (Download financials)

Ticker: VTVT
Share price, USD:  (-2.8%)24.04
year average price 20.48  


year start price 30.22 2023-04-21

max close price 37.89 2023-05-17

min close price 7.89 2024-01-25

current price 24.04 2024-04-19
Common stocks: 81 483 600

Dividend Yield:  0.0%
Last revenue growth (y/y):  > 200.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  12.5%
Historical growth of EBITDA:  ---
EV / Sales: 337.8x
Margin (EBITDA LTM / Revenue): -266.7%
Fundamental value created in LTM:
Market Cap ($m): 2 016
Net Debt ($m): 11
EV (Enterprise Value): 2 027
Price to Book: -81.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-06-15PRNewsWire

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VTVT VTVT VTVT VTVT VTVT VTVT
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-13 2023-11-09 2023-08-11 2023-05-11 2023-03-06 2022-11-10
acceptedDate 2024-03-13 07:58:44 2023-11-09 16:30:31 2023-08-11 16:40:54 2023-05-11 16:09:36 2023-03-06 17:30:33 2022-11-10 17:06:43
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 9000.000 0 9000.000 0
costOfRevenue 23 000 22 000 23 000 0 0 0
grossProfit -23 000 -22 000 -14 000 0 9000.000 0
grossProfitRatio 0 0 -1.556 0 1.000 1.000
researchAndDevelopmentExpenses 2M 3M 5M 4M 4M 3M
generalAndAdministrativeExpenses 3M 3M 3M 3M 2M 3M
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 3M 3M 3M 3M 2M 3M
otherExpenses 185 000 -3M 638 000 2M 107 000 0
operatingExpenses 5M 5M 8M 7M 6M 6M
costAndExpenses 5M 5M 8M 7M 6M 6M
interestIncome 88 000 131 000 153 000 100 000 152 000 150 000
interestExpense 7000.000 -4000.000 2000.000 -2M 6000.000 8000.000
depreciationAndAmortization 23 000 22 000 23 000 2M 259 000 253 000
ebitda -5M -7M -7M -6M -6M -5M
ebitdaratio 0 0 -798.444 0 -676.000 0
operatingIncome -5M -7M -8M -7M -6M -6M
operatingIncomeRatio 0 0 -888.889 0 -704.778 0
totalOtherIncomeExpensesNet 266 000 -3M 638 000 2M 253 000 221 000
incomeBeforeTax -4M -7M -7M -6M -6M -5M
incomeBeforeTaxRatio 0 0 -801.222 0 -676.667 0
incomeTaxExpense -963 000 -3M -952 000 -1M -199 800 -1M
netIncome -3M -7M -6M -4M -6M -4M
netIncomeRatio 0 0 -624.333 0 -654.467 0
eps -1.670 -3.270 -0.069 -0.055 -0.072 -0.053
epsdiluted -1.670 -3.270 -0.069 -0.055 -0.072 -0.053
weightedAverageShsOut 2M 2M 81M 81M 81M 80M
weightedAverageShsOutDil 2M 2M 81M 81M 81M 80M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VTVT VTVT VTVT VTVT VTVT VTVT
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-13 2023-11-09 2023-08-11 2023-05-11 2023-03-06 2022-11-10
acceptedDate 2024-03-13 07:58:44 2023-11-09 16:30:31 2023-08-11 16:40:54 2023-05-11 16:09:36 2023-03-06 17:30:33 2022-11-10 17:06:43
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 9M 8M 13M 19M 12M 15M
shortTermInvestments 0 0 15 000 0 0 0
cashAndShortTermInvestments 9M 8M 13M 19M 12M 15M
netReceivables 102 000 0 0 0 12M 12M
inventory 0 0 0 0 15 000 0
otherCurrentAssets 1M 2M 1M 2M 3M 1M
totalCurrentAssets 11M 10M 14M 21M 27M 29M
propertyPlantEquipmentNet 361 000 412 000 461 000 509 000 556 000 558 000
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0
longTermInvestments 0 4M 8M 8M 6M 6M
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 0 0 0 0 0 0
totalNonCurrentAssets 361 000 5M 8M 8M 6M 7M
otherAssets 0 0 0 0 0 0
totalAssets 11M 15M 22M 29M 33M 36M
accountPayables 10M -17 000 -17 000 0 2M 0
shortTermDebt 360 000 638 000 161 000 157 000 378 000 765 000
taxPayables 0 0 0 0 0 0
deferredRevenue 17 000 17 000 17 000 17 000 17 000 26 000
otherCurrentLiabilities 0 10M 9M 8M 5M 7M
totalCurrentLiabilities 11M 10M 9M 9M 8M 7M
longTermDebt 169 000 213 000 256 000 297 000 338 000 333 000
deferredRevenueNonCurrent 19M 19M 19M 19M 19M 19M
deferredTaxLiabilitiesNonCurrent 0 -19M -19M 0 0 0
otherNonCurrentLiabilities 110 000 19M 19M 21M 17M 44M
totalNonCurrentLiabilities 19M 19M 20M 39M 36M 45M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 169 000 378 000 417 000 454 000 492 000 541 000
totalLiabilities 30M 29M 29M 48M 44M 52M
preferredStock 0 0 0 0 0 0
commonStock 27 000 1M 1M 1M 1M 1M
retainedEarnings -281M -281M -281M -274M -266M -267M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0
othertotalStockholdersEquity 256M 255M 254M 254M 254M 249M
totalStockholdersEquity -25M -25M -25M -19M -11M -17M
totalEquity -19M -15M -6M 408 000 -11M -17M
totalLiabilitiesAndStockholdersEquity 11M 15M 22M 29M 50M 36M
minorityInterest 6M 11M 19M 20M 17M 0
totalLiabilitiesAndTotalEquity 11M 15M 22M 29M 50M 36M
totalInvestments 0 4M 8M 8M 6M 6M
totalDebt 529 000 851 000 417 000 454 000 716 000 1M
netDebt -9M -7M -12M -18M -11M -14M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VTVT VTVT VTVT VTVT VTVT VTVT
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-13 2023-11-09 2023-08-11 2023-05-11 2023-03-06 2022-11-10
acceptedDate 2024-03-13 07:58:44 2023-11-09 16:30:31 2023-08-11 16:40:54 2023-05-11 16:09:36 2023-03-06 17:30:33 2022-11-10 17:06:43
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -3M -9M -7M -6M -6M -5M
depreciationAndAmortization 23 000 22 000 23 000 22 000 23 000 24 000
deferredIncomeTax 108 000 0 -4M 0 0 0
stockBasedCompensation 403 000 433 000 399 000 343 000 291 000 338 000
changeInWorkingCapital 1M -48 000 1M 2M -820 000 -4M
accountsReceivables -102 000 0 0 173 000 -116 000 20 000
inventory 0 0 0 0 0 0
accountsPayables 659 000 500 000 738 000 1M -2M 0
otherWorkingCapital 729 000 -548 000 522 000 -1M 832 856 -4M
otherNonCashItems -1M 3M 3M -2M -284 000 -220 000
netCashProvidedByOperatingActivities -3M -5M -6M -5M -7M -9M
investmentsInPropertyPlantAndEquipment 0 0 0 0 20 979 0
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 4M 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0
netCashUsedForInvestingActivites 4M 0 0 0 20 979 0
debtRepayment -12M -93 000 0 -224 000 -333 000 -219 000
commonStockIssued 12M 0 0 12M 5M 0
commonStockRepurchased 0 0 1M 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 0 566 000 -1M 0 -1M 7M
netCashUsedProvidedByFinancingActivities -282 000 473 000 1M 12M 4M 6M
effectOfForexChangesOnCash 0 0 0 0 -20 979 0
netChangeInCash 1M -4M -6M 7M -3M -3M
cashAtEndOfPeriod 9M 8M 13M 19M 12M 15M
cashAtBeginningOfPeriod 8M 13M 19M 12M 15M 18M
operatingCashFlow -3M -5M -6M -5M -7M -9M
capitalExpenditure 0 0 0 0 20 979 0
freeCashFlow -3M -5M -6M -5M -7M -9M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-03-04 13:00 ET
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
2024-03-01 13:00 ET
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
2024-02-28 13:00 ET
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
2024-02-22 21:00 ET
CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE
2023-11-09 21:30 ET
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update
2023-11-08 13:00 ET
vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
2023-11-02 12:00 ET
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
2023-11-01 12:00 ET
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
2023-09-27 12:30 ET
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19
2023-09-26 12:30 ET
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer
2023-09-18 12:30 ET
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA
2023-08-11 20:30 ET
vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
2023-08-10 12:33 ET
Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer
2023-06-16 12:00 ET
vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline
2023-06-15 11:33 ET
CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON
2023-05-24 13:00 ET
vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
2023-05-11 20:15 ET
vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update
2023-04-20 12:00 ET
Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19
2023-03-06 22:56 ET
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
2023-03-06 13:02 ET
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
2023-02-27 13:02 ET
Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma
2023-02-01 22:00 ET
Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
2023-01-09 13:00 ET
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA
2022-12-13 13:15 ET
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
2022-11-10 22:25 ET
vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
2022-08-15 22:43 ET
vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update
2022-07-27 11:00 ET
vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer
2022-07-25 11:00 ET
vTv Therapeutics Announces Investment by CinRx Pharma
2022-06-04 15:00 ET
vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
2022-06-01 10:54 ET
vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare
2022-05-12 11:45 ET
vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update
2022-03-30 01:47 ET
vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update
2022-03-04 01:48 ET
vTv Therapeutics Announces CEO Transition
2022-01-13 13:30 ET
vTv Therapeutics Shares Updated Corporate Presentation
2021-12-06 22:19 ET
vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
2021-11-09 13:30 ET
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
2021-10-20 13:00 ET
vTv Therapeutics Announces Deepa Prasad as New President and CEO
2021-10-12 11:30 ET
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
2021-09-23 20:30 ET
vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
2021-08-04 20:30 ET
vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update
2021-06-29 11:30 ET
vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737
2021-06-22 11:30 ET
vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer
2021-05-05 20:10 ET
vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update
2021-04-13 11:30 ET
vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes
2021-04-12 20:30 ET
TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin
2021-03-23 11:30 ET
vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399
2021-03-18 20:05 ET
vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
2021-03-08 21:05 ET
vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
2021-02-24 21:30 ET
vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
2021-02-23 15:30 ET
vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes
2021-02-17 21:05 ET
vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
2021-01-06 21:30 ET
vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually
2020-12-15 23:15 ET
vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes
2020-12-15 14:05 ET
Aditum Bio Announces Formation of Third Company, Anteris Bio
2020-12-15 12:30 ET
vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio
2020-11-24 21:30 ET
vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital
2020-11-05 21:30 ET
vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update
2020-11-04 12:30 ET
vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study
2020-10-29 11:30 ET
vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event
2020-09-23 11:30 ET
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes
2020-09-16 11:30 ET
vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting
2020-09-15 11:30 ET
vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors
2020-08-03 20:30 ET
vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update
2020-07-27 11:30 ET
vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference
2020-06-13 15:00 ET
vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients
2020-05-22 20:30 ET
vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format
2020-05-07 20:30 ET
vTv Therapeutics Announces 2020 First Quarter Financial Results and Update
2020-02-20 23:57 ET
vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
2020-02-10 12:00 ET
vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
2020-02-07 21:05 ET
vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
2019-12-02 12:30 ET
vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
2019-10-30 21:30 ET
vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update
2019-10-03 11:30 ET
vTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin
2019-09-18 11:30 ET
vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes
2019-09-11 11:30 ET
vTv Therapeutics to Present Posters at Two Scientific Conferences in September

SEC forms

Show financial reports only

SEC form 8
2024-03-13 00:00 ET
vTv Therapeutics published news for 2023 q4
SEC form 8
2024-03-13 00:00 ET
vTv Therapeutics reported for 2023 q4
SEC form 10
2024-03-13 00:00 ET
vTv Therapeutics published news for 2023 q4
SEC form 10
2023-11-09 16:30 ET
vTv Therapeutics reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
vTv Therapeutics reported for 2023 q3
SEC form 10
2023-08-11 16:40 ET
vTv Therapeutics reported for 2023 q2
SEC form 6
2023-08-11 16:36 ET
vTv Therapeutics reported for 2023 q2
SEC form 10
2023-08-11 00:00 ET
vTv Therapeutics reported for 2023 q2
SEC form 8
2023-08-11 00:00 ET
vTv Therapeutics reported for 2023 q2
SEC form 6
2023-07-20 16:22 ET
vTv Therapeutics published news for 2023 q2
SEC form 6
2023-06-26 16:24 ET
vTv Therapeutics published news for 2023 q1
SEC form 6
2023-06-08 16:24 ET
vTv Therapeutics published news for 2023 q1
SEC form 10
2023-05-11 16:09 ET
vTv Therapeutics reported for 2023 q1
SEC form 6
2023-05-11 16:06 ET
vTv Therapeutics reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
vTv Therapeutics reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
vTv Therapeutics reported for 2023 q1
SEC form 10
2023-03-06 17:30 ET
vTv Therapeutics reported for 2022 q4
SEC form 6
2023-03-06 17:29 ET
vTv Therapeutics reported for 2022 q4
SEC form 6
2023-03-06 16:30 ET
vTv Therapeutics published news for 2022 q4
SEC form 8
2023-03-06 00:00 ET
vTv Therapeutics reported for 2022 q4
SEC form 10
2023-03-06 00:00 ET
vTv Therapeutics reported for 2022 q4
SEC form 6
2023-02-01 17:06 ET
vTv Therapeutics published news for 2022 q4
SEC form 6
2023-01-06 17:20 ET
vTv Therapeutics published news for 2022 q4
SEC form 6
2022-12-23 16:35 ET
vTv Therapeutics published news for 2022 q3
SEC form 6
2022-12-13 17:00 ET
vTv Therapeutics published news for 2022 q3
SEC form 6
2022-12-13 09:02 ET
vTv Therapeutics published news for 2022 q3
SEC form 10
2022-11-10 17:06 ET
vTv Therapeutics reported for 2022 q3
SEC form 6
2022-11-10 16:57 ET
vTv Therapeutics reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
vTv Therapeutics reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
vTv Therapeutics reported for 2022 q3
SEC form 6
2022-08-18 19:00 ET
vTv Therapeutics published news for 2022 q2
SEC form 6
2022-08-17 09:40 ET
vTv Therapeutics published news for 2022 q2
SEC form 10
2022-08-15 18:15 ET
vTv Therapeutics reported for 2022 q2
SEC form 6
2022-08-15 18:15 ET
vTv Therapeutics reported for 2022 q2
SEC form 6
2022-08-15 17:47 ET
vTv Therapeutics published news for 2022 q2
SEC form 8
2022-08-15 00:00 ET
vTv Therapeutics reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
vTv Therapeutics published news for
SEC form 6
2022-07-27 07:26 ET
vTv Therapeutics published news for 2022 q2
SEC form 6
2022-07-25 07:11 ET
vTv Therapeutics published news for 2022 q2
SEC form 6
2022-07-15 16:37 ET
vTv Therapeutics published news for 2022 q2
SEC form 6
2022-06-10 20:31 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 16:10 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-06-03 16:01 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-06-01 07:38 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-05-12 06:07 ET
vTv Therapeutics published news for 2022 q1
SEC form 10
2022-05-12 06:05 ET
vTv Therapeutics reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
vTv Therapeutics reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
vTv Therapeutics reported for 2022 q1
SEC form 6
2022-05-02 17:20 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-04-15 16:31 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-04-05 17:21 ET
vTv Therapeutics published news for 2022 q1
SEC form 6
2022-04-05 16:08 ET
vTv Therapeutics published news for 2022 q1
SEC form 10
2022-03-29 17:29 ET
vTv Therapeutics published news for 2021 q4
SEC form 6
2022-03-29 17:24 ET
vTv Therapeutics published news for 2021 q4
SEC form 10
2022-03-29 00:00 ET
vTv Therapeutics published news for 2021 q4
SEC form 8
2022-03-29 00:00 ET
vTv Therapeutics published news for 2021 q4
SEC form 6
2022-03-03 17:23 ET
vTv Therapeutics published news for 2021 q4
SEC form 6
2022-02-18 16:27 ET
vTv Therapeutics published news for 2021 q4
SEC form 6
2021-12-06 17:35 ET
vTv Therapeutics published news for 2021 q3
SEC form 6
2021-12-02 17:17 ET
vTv Therapeutics published news for 2021 q3
SEC form 6
2021-11-09 08:46 ET
vTv Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 08:39 ET
vTv Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
vTv Therapeutics published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
vTv Therapeutics published news for 2021 q3
SEC form 6
2021-10-20 09:00 ET
vTv Therapeutics published news for 2021 q3
SEC form 10
2021-08-04 16:46 ET
vTv Therapeutics published news for 2021 q2
SEC form 6
2021-08-04 16:35 ET
vTv Therapeutics published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
vTv Therapeutics published news for 2021 q2
SEC form 6
2021-06-25 16:35 ET
vTv Therapeutics published news for 2021 q1
SEC form 6
2021-05-05 16:37 ET
vTv Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 16:30 ET
vTv Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
vTv Therapeutics published news for 2021 q1
SEC form 6
2021-03-18 07:30 ET
vTv Therapeutics published news for 2020 q4
SEC form 6
2021-03-08 16:17 ET
vTv Therapeutics published news for 2020 q4
SEC form 6
2021-02-24 16:55 ET
vTv Therapeutics published news for 2020 q4
SEC form 10
2021-02-24 16:49 ET
vTv Therapeutics published news for 2020 q4
SEC form 6
2021-01-21 16:05 ET
vTv Therapeutics published news for 2020 q4
SEC form 6
2021-01-14 17:15 ET
vTv Therapeutics published news for 2020 q4
SEC form 6
2020-12-30 16:30 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-12-17 16:30 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-12-15 07:51 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-12-10 16:30 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-11-24 16:30 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-11-17 16:30 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-11-05 16:53 ET
vTv Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 16:32 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-10-26 07:00 ET
vTv Therapeutics published news for 2020 q3
SEC form 6
2020-10-02 17:00 ET
vTv Therapeutics published news for 2020 q3